By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the past year there were no insider purchases at BridgeBio Pharma, Inc.. Ten insiders sold roughly $118.4 million instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Members of Congress reported 7 trades in BBIO over the past two years (one member). Big money check: 474 institutions held BBIO as of Q2 2026, and funds were split between buying and selling. Quarter by quarter: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
Are insiders buying or selling BBIO stock?
In the last 12 months BridgeBio Pharma, Inc. insiders made open-market purchases worth about $0 and sales worth about $118.4 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in BBIO?
The most recent open-market insider trade in BBIO was filed on 2026-09-21.
How many institutions own BBIO?
474 investment managers reported holding BBIO in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded BBIO?
Yes. Members of Congress reported 7 trades in BBIO over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).